Prostate Cancer Trial, Recruiting NCT07541911 Sponsor: University College, London Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07541911
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a clinically significant form of prostate cancer that can be treated with surgery, at a specific stage where the cancer has not spread to nearby lymph nodes or other parts of the body.
  • People who are healthy enough to undergo a type of prostate removal surgery performed with robotic assistance.
  • People whose medical team — based on MRI scans, biopsy results, and other clinical information — has recommended that a specific surgical technique (one that avoids cutting too close to the nerves near the prostate) be used on at least one side during the operation.
  • People who are able to read English well enough to understand the participant information sheet and give their agreement to take part in the trial.

Who may not be able to join:

  • People who have received hormone therapy (a treatment that lowers testosterone) before surgery.
  • People whose MRI scan shows a very low likelihood that the cancer has grown beyond the prostate near the nerve bundles on the side of the prostate (confirm with trial site for exact scoring details).
  • People whose MRI scan shows a high likelihood that the cancer has grown well beyond the prostate near the nerve bundles (confirm with trial site for exact scoring details).
  • People whose scans show the cancer may have spread into the rectum or the seminal vesicles, where nerve-sparing surgery is considered unsafe from a cancer control perspective.
  • People who have previously received any treatment for prostate cancer, including radiation therapy, internal radiation (brachytherapy), targeted local treatments (focal therapy), or chemotherapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Greg Shaw, Professor, University College, London

Phone: +44 02076792000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 April 2026
Est. completion
20 May 2030

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Sensitivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov